姓 名： 谭大清
性 别：男
最高学位：博士
职 称：副主任医师
职 务：副主任
E-mail：tandaqing1982@163.com
研究方向：泌尿外科学
个人简介：
湖北民族大学附属民大医院泌尿外科副主任，副主任医师，医学博士，硕士生导师。湖北省泌尿外科腔镜技术联盟委员、恩施州男科学会委员。曾取得腔镜泌尿外科高级培训班合格证书及中国医师协会腹腔镜外科医师培训学院合格证，曾获第二届国际尿石症联盟（IAU）全国泌尿医生结石知识竞赛中部赛区决赛三等奖。从事泌尿外科临床、教学、科研工作近20年，擅长泌尿系统疾病的诊治与微创治疗，以主要研究者身份参与国家民委项目1项、国家自然科学基金青年科学基金项目1项及高等学校博士学科点专项科研基金项目1项，发表SCI及北大核心等论文10余篇。
公开发表论文、教材、专著及课程建设：
1.Tan D, Li J, Lin T, Tan P, Zhang J, Xiong Q, et al. Prognostic Utility of the Modified Glasgow Prognostic Score in Urothelial Carcinoma: Outcomes from a Pooled Analysis. J Clin Med. 2022;11(21).
2.Tan DQ. Influence of ABCB1 (1236C > T, 2677G > T and 3435C > T) polymorphisms on the transport ability of P-gp-mediated sunitinib in Caco-2 cell line. Xenobiotica. 2020;50(3):346-53.
3.Jiang J, Li J, Xiong X, Zhang S, Tan D, Yang L, et al. Different predictive values of microvessel density for biochemical recurrence among different PCa populations: A systematic review and meta-analysis. Cancer Med. 2022.
4.Li J, Cao D, Huang Y, Xiong Q, Tan D, Liu L, et al. The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer. Front Immunol. 2022;13:865643.
5.Li J, Huang Y, Zhu M, Chen M, Xiong Q, Tan D, et al. Does Moses technology enhance the efficiency and outcomes of regular holmium laser lithotripsy? Results of a pooled analysis of comparative studies. Lasers Med Sci. 2023;38(1):73.
6.Yao Y, Zhang J, Tan DQ, Chen XY, Ye DF, Peng JP, et al. Interferon-gamma improves renal interstitial fibrosis and decreases intrarenal vascular resistance of hydronephrosis in an animal model. Urology. 2011;77(3):761 e8-13.
7.Yao Y, Zhang J, Ye DF, Tan DQ, Peng JP, Xie M, et al. Left-right determination factor is down-regulated in fibrotic renal tissue of human hydronephrosis. BJU Int. 2011;107(6):1002-8.
8.Zhang L, Liang J, Liu X, Wu J, Tan D, Hu W. Aloperine Exerts Antitumor Effects on Bladder Cancer in vitro. Onco Targets Ther. 2020;13:10351-60.
9.Zhang L, Liu X, Liang J, Wu J, Tan D, Hu W. Lefty-1 inhibits renal epithelial-mesenchymal transition by antagonizing the TGF-beta/Smad signaling pathway. J Mol Histol. 2020;51(1):77-87.